Pall ForteBio Launches the Octet K2 System, Increasing Access to Sensitive Binding Interactions Analysis
Pall ForteBio has launched the Octet K2 system, a new entry point into the Octet line of label-free interaction analysis systems. Now available globally, the Octet K2 system offers high-performance, budget-friendly kinetic characterization of antibody, protein and small-molecule binding interactions.
Using Pall ForteBio’s Bio-Layer Interferometry (BLI) technology, all Octet systems offer a fluidics-free alternative to surface plasmon resonance with a variety of off-the-shelf Dip and Read biosensors for more rapid assay development and optimization. The Octet K2 system increases accessibility to BLI as a two-channel instrument, providing exquisite binding affinity data for molecules down to 150 daltons in size.
“Label-free users in academia and at startup biotech companies have historically been stuck between choosing to pay a premium for capacity they will never use or to settle for a lower-performance ‘starter’ system,” commented Robert Wicke, General Manager at Pall ForteBio. “The Octet K2 system offers scientists throughput to meet their budget without compromising assay sensitivity.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.